FAB122

DRUG2 trials

Sponsors

Ferrer Internacional S.A.

Conditions

Amyotrophic Lateral Sclerosis

Phase 3

Study to Investigate the Efficacy and Safety of FAB122 (Daily Oral Edaravone) in Patients With Amyotrophic Lateral Sclerosis

CompletedNCT05178810

Ferrer Internacional S.A.Amyotrophic Lateral Sclerosis

Start: 2021-10-18End: 2023-10-26Updated: 2025-03-18

Study to Investigate the Long-term Safety of FAB122 in Patients With Amyotrophic Lateral Sclerosis

TerminatedNCT05866926

Ferrer Internacional S.A.Amyotrophic Lateral Sclerosis

Start: 2023-03-06End: 2024-02-22Updated: 2025-03-04